#United States #Friendswood #CFO Award #Castle Biosciences #Frank Stokes

Frank Stokes of Castle Biosciences Receives 2026 CFO Award

Castle Biosciences, Inc., a healthcare company dedicated to improving patient care through innovative diagnostic tests, has recently announced a significant milestone in its leadership. Frank Stokes, the Chief Financial Officer (CFO) of the company, has been honored with the prestigious 2026 CFO Awards by the Houston Business Journal.

Celebrating Financial Excellence in Houston

On June 23, 2026, this recognition was unveiled, showcasing Stokes as one of 22 high-caliber financial executives from the Greater Houston area. The award highlights not only his individual contributions but also his commitment to fostering an environment where financial discipline meets strategic innovation.

The Houston Business Journal’s CFO Awards, scheduled for July 30, will celebrate these honorees, with their achievements further detailed in both print and digital formats on July 31. As noted by Derek Maetzold, President and CEO of Castle Biosciences, Stokes exemplifies the blend of financial acumen and visionary leadership that has propelled the company’s growth trajectory since he assumed the role of CFO in December 2017.

A Legacy of Strategic Growth

Under Stokes' financial stewardship, Castle Biosciences successfully navigated its initial public offering and has been pivotal in advancing the company's strategic growth through various key acquisitions. His leadership during this critical phase has not only shaped the company’s operational strategy but has also enhanced its ability to serve patients effectively.

Stokes expressed gratitude for the recognition, stating, "It is an honor to be recognized among so many outstanding financial leaders in Houston. I am proud to work alongside a talented team at Castle as we advance our mission of improving patient care through innovative testing solutions."

Prior to this latest accolade, Frank Stokes was honored as a Top 25 CFO of Houston by TOP CFOs in both 2024 and previously. These repeated acknowledgments emphasize his commitment to excellence in financial management and corporate responsibility, further underlining his pivotal role in the success story of Castle Biosciences.

About Castle Biosciences

Castle Biosciences, traded on Nasdaq under the ticker CSTL, is renowned for its innovative approach to diagnostics, particularly in the areas of dermatological and gastroenterological diseases. The company is committed to delivering personalized tests that enable more effective healthcare decisions, thus enhancing disease management and patient outcomes.

Their focus on scientific rigor and advanced molecular testing methodologies reflects their objective to empower both patients and clinicians. Some of the innovative tests they provide include DecisionDx-Melanoma, DecisionDx-CMSeq, and others, all of which play a critical role in individualized patient care.

For more information on Castle Biosciences and their groundbreaking work, visit www.CastleBiosciences.com and check out their presence on social media platforms including LinkedIn, Instagram, Facebook, and X.

In conclusion, the recognition of Frank Stokes by the Houston Business Journal is not only a testament to his individual capabilities but also represents Castle Biosciences’ ongoing dedication to improving health through innovative diagnostic solutions. As they look forward to further advancements in the healthcare landscape, Stokes' leadership will undoubtedly continue to play a crucial role in the company's future successes.